Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 4, 2011, Pages 558-565

  Bashey, Asad ^a,b   Owzar, Kouros ^c   Johnson, Jeffrey L ^c   Edwards, Peggy S ^c   Kelly, Michael ^d   Baxter Lowe, Lee Ann ^e   Devine, Steven ^f   Farag, Sherif ^g   Hurd, David ^h   Ball, Edward ^a   McCarthy, Philip ⁱ   Lister, John ^j   Shea, Thomas C ^k   Linker, Charles ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHSIDE HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j WESTERN PENNSYLVANIA HOSPITAL   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Allogeneic; Autologous; Reduced intensity conditioning; Relapse; Second transplant

Indexed keywords

BUSULFAN; CD3 ANTIGEN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CHIMERA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; SIBLING;

ADOLESCENT; ADULT; AGED; ANIMALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RABBITS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952622436     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.015     Document Type: Article

References (20)

1. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.
2. Chiang K.Y., Weisdorf D.J., Davies S.M., et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996, 17:39-42.
3. Tsai T., Goodman S., Saez R., et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997, 20:859-863.
4. Ringden O., Labopin M., Frassoni F., et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999, 24:389-396.
5. Blau I.W., Basara N., Bischoff M., et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000, 25:41-45.
6. Nagler A., Or R., Naparstek E., Varadi G., Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000, 28:1096-1104.
7. Radich J.P., Gooley T., Sanders J.E., Anasetti C., Chauncey T., Appelbaum F.R. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000, 6:272-279.
8. Branson K., Chopra R., Kottaridis P.D., et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031.
9. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006, 24:4150-4157.
10. Thomson K.J., Peggs K.S., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:765-770.
11. Scharf S.J., Smith A.G., Hansen J.A., McFarland C., Erlich H.A. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995, 85:1954-1963.
12. Freytes C.O., Loberiza F.R., Rizzo J.D., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004, 104:3797-3803.
13. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24:5695-5702.
14. Moore J., Nivison-Smith I., Goh K., et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007, 13:601-607.
15. Schetelig J., Bornhauser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
16. Hows J.M., Passweg J.R., Tichelli A., et al. Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant 2006, 38:799-805.
17. Valcarcel D., Martino R., Caballero D., et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003, 31:387-392.
18. Mohty M., Avinens O., Faucher C., Viens P., Blaise D., Eliaou J.F. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007, 92:1004-1006.
19. Saito B., Fukuda T., Yokoyama H., et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1148-1155.
20. Nakai K., Mineishi S., Kami M., et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003, 75:2135-2143.